SynthesisCalcified tissue international2026
Extracellular Vesicles for Treatment of Bone Resorption-Related Diseases in Animal Models: Systematic Review.
Synthesis in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review aimed to analyze the usefulness of EV therapy in controlling bone resorption-related diseases in animal models. The study was conducted following the PRISMA guidelines. The search was conducted until November 2025 using PubMed/MEDLINE, Scopus, Cochrane Library, and OpenGrey databases to respond to the PICO question: Would therapy with EVs be efficient for the treatment of bone resorption-related diseases in vivo? The primary and secondary outcomes were the control of bone resorption and the molecular mechanisms involved, respectively. The risk of bias was examined according to the criteria of SYRCLE's RoB tool. A total of 1031 studies were reviewed, and after applying the eligibility criteria and excluding duplicates, 38 articles were included in the results. The usefulness of EVs in controlling bone resorption was established in the majority of studies. Increased levels of osteoprotegerin (OPG) and decreased levels of the pro-inflammatory cytokines, receptor activator of nuclear factor-kB ligand (RANKL), tartrate-resistant acid phosphatase (TRAP), and osteoclasts were reported. The studies also showed enhanced levels of alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx2), and osteocalcin (OCN), contributing to increased bone density. EV is a promising treatment for bone resorption-related diseases in vivo. Further studies are needed to assess safety, optimal dosing, and ideal source cells, in order to confirm the findings and support potential investigations in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.